B-cell Lymphoma Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for b-cell lymphoma in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

    The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with sep…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Fox Chase Cancer Center, Philadelphia, Pennsylvania
    Locations
    49 in total
    Run by
    BeOne Medicines

    See if you can join NCT06634589 on ClinicalTrials.gov

  2. A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

    The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
    Locations
    51 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07101328 on ClinicalTrials.gov

  3. Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

    The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, n…

    Stage
    Not phased
    Ages
    0 to 38
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Locations
    5 in total
    Run by
    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT06131801 on ClinicalTrials.gov

  4. SynKIR-310 for Relapsed/Refractory B-NHL

    This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    5 in total
    Run by
    Verismo Therapeutics

    See if you can join NCT06544265 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.